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Summary. Serial immunological monitoring was per- 
formed on 31 patients with Ewing's sarcoma who were 
on a randomized immunotherapy trial with BCG ad- 
ministered by dermal scarification with a Heaf gun. Pa- 
tients were skin-tested for delayed hypersensitivity reac- 
tions (DCHR) to recall antigens and extracts of tumor 
cells, and with keyhole limpet hemoeyanin (KLH). In 
vitro testing consisted of lymphocyte counts, percentages 
of cells forming rosettes with sheep erythrocytes at 29 ° 
C and at 4 ° C, and leukocyte migration inhibition to 
tuberculin (PPD) and to 3 M KCl extracts of tumor 
cells. At the time of diagnosis, nearly all patients had 
positive DCHR to mumps and streptococcal antigens 
and were negative to PPD. Neither the skin tests nor the 
lymphocyte counts at this time gave useful prognostic 
information. In tests during and after therapy, the pa- 
tients who responded and remained free of detectable 
disease had a higher ineidenee of DCHR to KLH and of 
rosette values in the normal range than did the patients 
who developed recurrent disease. The BCG immuno- 
therapy had no apparent effect on immunologic parame- 
ters except for conversion of reactions to PPD. 
Introduction 
Ewing's sarcoma is a highly malignant undifferentiated 
tumor arising in bone and, rarely, in soft tissues (Anger- 
vail and Enzinger, 1975). It is an uncommon tumor, 
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accounting for about 10% of all malignant primary bone 
tumors, but nevertheless, after osteogenic sarcoma, it is 
the most common malignant primary bone neoplasm. 
When treated by either surgical resection or local radio- 
therapy alone, there is an equally grim prognosis: about 
50% of such patients relapse with distant metastases 
within 12 months (Sutow and Martin, 1974) and fewer 
than 10% survive 5 years (Johnson and Pomeroy, 1972; 
Falk and Alpert, 1967; Rosen et al., 1974). Because of 
the high probability of occult metastases being present 
at the time of diagnosis, most centers now combine local 
radiotherapy to the primary lesion with adjuvant che- 
motherapy. Such therapeutic strategies have resulted in 
impressive improvements in both remission duration 
and 5-year survival rates (Rosen et al., 1974; Johnson 
and Pomeroy, 1975; Jaffe et al., 1976). Of 125 Ewing's 
sarcoma patients treated at the National Cancer Insti- 
tute since 1964, 70% were alive at 2 years and 16% 
survived 5 years after treatment. For patients without 
clinical evidence of metastases at diagnosis the figures 
are even more striking: of 46 patients treated with radio- 
therapy to the primary lesion and with adjuvant chemo- 
therapy (cyclophosphamide, doxorubicin, and vincris- 
tine), 70% are disease-free and 89% are alive 30 months 
after completion of treatment. 
We previously reported a correlation between the 
presence of perivascular infiltrates of small lymphocytes 
in the supporting stroma of Ewing's sarcoma and subse- 
quent survival (Pomeroy and Johnson, 1975). Because 
of this suggestion of the role of the immune response in 
this disease and because of our interest in the immuno- 
logic status of cancer patients, in 1974 we began a study 
of immunologic monitoring and immunotherapy in 
Ewing's sarcoma. This report describes our findings 
with a variety of in vivo and in vitro assays of immune 
reactivity in such patients. A number of patients were 
treated with immunostimulants, and the effects of this 
therapy were monitored by observation of their clinical 
courses in addition to their immunologic responses. 
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Materials and Methods 
61 patients with Ewing's sarcoma were studied over a 2-year period 
at the National Cancer Institute. For the purposes of this study these 
patients were classified into the following groups: 
Group A: Patients without clinical evidence of metastases at 
diagnosis and no evidence of tumor recurrence after completion of 
therapy (29 patients). 
Group B: Patients without clinical evidence of metastases at 
diagnosis but tumor recurrence after completion of therapy (17 pa- 
tients). 
Group C: Patients with clinically apparent metastases at diagno- 
sis (15 patients). 
Treatment regimens have been described by Johnson and Pome- 
roy (i 976). All patients were treated with chemotherapy in combina- 
tion with 5000 R to the primary site, given over a period of five 
weeks. 55 patients were treated with the $4 protocol (doxorubicin, 
cyclophosphamide, vincristine, and CNS prophylactic irradiation). 
Because of the poor prognosis of patients with metastatic disease, 
particularly those with bulky tumors, a number of group C patients 
were treated with an accelerated $4 regimen utilizing the same radio- 
therapy and CNS prophylaxis plus a more intensive chemothera- 
peutic program employing the same three drugs given together every 
3 weeks. Six patients were treated according to earlier protocols; 
three of these were treated according to the $3 protocol, with CNS 
prophylactic irradiation plus cyclophosphamide, vincristine, and 
dactinomycin; two according to $2 with cyclophosphamide and vin- 
cristine; and one according to S1 with cyclophosphamide. 
In addition to radio- and chemotherapy, 11 group C patients 
were randomized to receive immunotherapy with either BCG (baeille 
Calmette Gu+rin) or BCG plus allogeneic irradiated tumor cells. 
Nine patients in group B were also treated with BCG immunother- 
apy, with or without irradiated allogeneic tumor cells. Finally, nine 
patients with clinically localized disease who were at high risk for 
recurrence by virtue of either truncal location of the primary tumor 
(Pomeroy and Johnson, 1975) or a serum lactate dehydrogenase 
(LDH) level greater than 200 IU (Brereton et al., 1975) were ran- 
domized to BCG immunotherapy or no further therapy, in addition 
to radiotherapy and adjuvant chemotherapy. 
BCG was administered by dermal scarification using a 20-point 
Heal gun. Lyophilized Pasteur BCG, 6 _+ 4 x l0 s viable organisms 
per vial, was diluted in less than 1 ml of normal saline and applied to 
an area of skin 5 x 5 cm for each scarification. BCG was given on 
days 14, 28, and 42 of each 49-day chemotherapy cycle, and for 
patients with recurrent or progressive disease at day 14 of the 21-day 
chemotherapy cycle. Immunizations were given in a single extremity, 
and the immunization sites were rotated sequentially, avoiding ex- 
tremities treated by radiotherapy. Patients treated with BCG plus 
allogeneic tumor cells received BCG in identical fashion. Allogeneic 
cells were obtained at surgery or necropsy under sterile conditions 
from metastatic sites, manually dispersed, suspended in tissue culture 
medium with 10% dimethylsulfoxide, and stored in vapor-phase liq- 
uid nitrogen. Cell preparations were cultured for possible bacterial 
contamination, and only used when found to be sterile. Prior to injec- 
tion the thawed cell suspension was irradiated with 5000 R, and 107 
allogeneic cells were injected intradermally and subcutaneously 1 cm 
from the margin of the last BCG inoculation. The intention was to 
have the major lymph node groups stimulated with BCG prior to 
injection of the allogeneic tumor cells, and to have a separate site for 
the cell inoculum to permit observation, in the unlikely event that the 
injected cells might grow. 
Delayed Cutaneous Hypersensitivity (DCH) 
Intradermal testing for delayed hypersensitivity was performed when 
possible prior to therapy and at 3-month intervals both during and 
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following therapy. All patients were tested with one or more of the 
following standard recall antigens: streptokinase-streptodornase (40 
U SK, 10 U SD/0.1 ml, Varidase, Lederle Laboratories Division, 
American Cyanamid Co., Pearl River, N.Y. 10965), PPD (5 TU/0.1 
ml, Parke Davis, Detroit, Mich. 48232), and mumps (20 U/0.1 ml, 
Eli Lilly and Co., Indianapolis, Ind. 46206). Patients were also tested 
for DCH to hypotonic membrane preparations (HMP) (Oren and 
Herberman, 1971) and 3 M KC1 extracts (McCoy et ai., 1975) of a 
Ewing's sarcoma (5838) obtained from pleural fluid at necropsy and 
of the established tissue culture line (5838 TC) derived from this 
specimen. After testing for sterility, 0.1 mg protein/0.1 ml quantifies 
of these preparations were injected intradermally. 
To assess the ability to respond to a new antigen, keyhole limpet 
hemocyanin (KLH), generously supplied by Dr. Michael Blaese, 
Metabolism Branch, NCI, 2.5 mg/0.5 ml was injected subcutaneous- 
ly prior to chemotherapy, and the response to 0.1 mg/0.1 ml KLH 
injected intradermaily was determined in the same manner as for the 
other antigens. 
DCH responses were read 48 h following intradermal injection 
of antigen using a ball-point pen technique similar to that described 
by Sokal (1975). Readings were recorded in mm of induration, and a 
skin test for any antigen was considered positive if it was 5 mm or 
greater in diameter. 
Direct Leukocyte Migration Inhibition 
Leukocyte migration inhibition (LMI) by either PPD or 3 M KC1 
extracts of the 5838 tumor or of the 5838 TC cell line was performed 
as described by McCoy et al. (1977). The migration index (MI) was 
calculated according to the formula 
mean migration area of 4 replicates in presence of antigen 
M I =  
mean migration area of 4 replicates in absence of antigen 
Migration indices of patients were compared to those of normals, 
and the number of positive MIs was determined, as previously de- 
scribed (McCoy et al., 1977), by means of a cutoff value calculated 
so that 10% of normal MIs fell below this value. MIs falling below 
this cutoff were considered positive, i.e., below the lower tenth per- 
centile of normals. Cutoff values were determined individually for 
PPD and for the 3 M KCI extracts of 5838 and 5838 TC. 
Rosettes 
Thymus-dependent lymphocytes were assayed when possible prior 
to therapy and at monthly intervals by determination of spontaneous 
rosette formation with sheep red blood cells (SRBC) at 4 ° C and at 
29 ° C as previously described (West, 1978; West et al., 1976). Ve- 
nous blood specimens were drawn prior to the administration of the 
next course of chemotherapy or after completion of chemotherapy. 
In our laboratory, normal donors tested for 4 ° C RFC and 29 ° C 
RFC by these techniques had a mean of 76% and 53%, respectively 
(Djeu et al., in press). Values falling below the tenth percentile of 
normais, 67% for 4 ° C RFC and 47% for 29 ° C RFC, were consid- 
ered depressed. 
Results 
Prognostic Value of Tests Performed before or during 
Therapy 
W e  were  i n t e r e s t ed  in w h e t h e r  D C H  r e s p o n s e s  to  recal l  
an t igens  a n d  T A A s  at  the  t ime  o f  d iagnos i s  m i g h t  be  o f  
s o m e  p r o g n o s t i c  value.  T a b l e  1 s u m m a r i z e s  these  re- 
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Table 1. DCH in Ewing's sarcoma patients tested at diagnosis 
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SKSD Mumps PPD 5838 KC1 5838 TC 5838 HMP 
KCI 
Group A: 14 patients Number of patients 13/13 3/3 2/14 7/8 8/11 2/11 
reactive/total tested 
(%) (100) (100) (14) (88) (73) (18) 
Group B: 5 patients Number of patients 4/4 2/2 0/4 1/1 0/1 1/3 
reactive/total tested 
(%) (100) (100) (0) (100) (0) (33) 
Group C: 7 patients Number of patients 5/5 2/3 0/7 1/1 2/3 2/6 
reactive/total tested 
(%) (100) (67) (0) (100) (67) (33) 
Table 2. Relationship of absolute lymphocyte count at diagnosis to clinical course 




Number of patients in range/number of 
patients in group (%) 
< 1000 4/29 (14) 1/16 (6) 5/45 (11) 4/13 (31) 
1000--2000 16/29 (55) 6/16 (38) 22/45 (49) 6/13 (46) 
> 2000 9/29 (31) 9/16 (56) 18/45 (40) 3/13 (23) 
Table 3. KLH skin test responses _> 15 mm induration during ther- 
apy 
Group A 
Number of patients reactive/total tested (%) 
Number of tests (+)/total tests (%) 
Group B 
Number of patients reactive/total tested (%) 3/6 (50) 
Number of tests (+)/total tests (%) 7/12 (58) 
Group C 
Number of patients reactive/total tested (%) 3/7 (43) 
Number of tests (+)/total tests (%) 3/10 (30) 
10/12 (83) 
13/17 (76) 
Differences between groups are not significant by chi-square analy- 
sis 
sults. Nearly all patients were reactive to SKSD and 
mumps and nonreactive to PPD. Few patients in groups 
B and C were tested with TAAs at diagnosis, but D C H  
responses to the TAAs at diagnosis roughly correspond- 
ed to the overall pattern of reactivity of each patient 
group. No pattern of reactivity distinguished patients 
with localized disease from those with metastases nor 
did it identify patients who would later relapse. 
Preliminary data had suggested that patients with 
total lymphocyte counts less than 1000 per mm 3 or 
greater than 2000 per mm 3 prior to treatment had a 
poorer prognosis than patients with counts in the range 
of 1000-2000 per mm 3. However, as shown in Table 2, 
pre-therapy lymphocyte counts between 1000 and 2000 
per mm 3 failed to indicate a significant pronostic benefit 
to non-metastatic patients and similarly failed to dis- 
criminate between patients with metastatic versus non- 
metastatic disease. 
In contrast to the lack of prognostic value of total 
lymphocyte counts and initial DCH responses to stan- 
dard recall and tumor-associated antigens, the magni- 
tude of the delayed hypersensitivity response to KLH 
during treatment appeared to distinguish patients in 
group A from those in groups B and C. As shown in 
Table 3, most of the patients in group A and fewer in 
groups B and C had responses to K L H  of 15 mm or 
greater. 
The results of skin tests of all antigens and of direct 
LMI during therapy in patients with localized disease 
are shown in Table 4. All patients who remained free of 
disease were reactive to KLH,  SKSD, or mumps, and 
with the exception of a single negative mumps test, all of 
the responses to these antigens were positive. In con- 
trast, several patients who later relapsed were unreactive 
to these antigens. Skin test reactivity to the tumor ex- 
tracts was similar for the disease-free patients and those 
who had recurrences, and corresponded to the overall 
reactivity to these antigens. LMI reactivity during ther- 
apy of group A patients was roughly equal to the overall 
responses for this group to the 3 M KC1 extract of 5838 
TC; too few group B patients were tested during pri- 
mary therapy to permit assessment of their LMI re- 
sponses. Four of seven group A patients reacted to PPD 
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Table 4. Immunologic reactivity during therapy and subsequent clinical course of patients with localized disease 
Delayed cutaneous hypersensitivity 
KLH SKSD Mumps PPD 5838 KC1 5838 TC KC1 5838 HMP 
Group A 
Number of patients reactive/total tested (%) 
Number of (+) tests/total tests (%) 
Group B 
Number of patients reactive/total tested (%) 
Number of (+) tests/total tests (%) 
14/14 10/10 I/1 3/7 7/7 5/9 2/9 
(100) (100) (100) (43) (100) (56) (22) 
19/19 14/14 1/2 4/11 7/8 5/9 2/12 
(100) (I00) (50) (36) (88) (56) (17) 
3/4 4/5 0/1 1/5 3/3 2/3 1/4 
(75) (80) (0) (20) (100) (67) (25) 
9/12 6/7 0/1 1/8 4/4 3/6 1/7 
(75) (86) (0) (13) (100) (50) (14) 
Leukocyte migration inhibition 
5838 TC 5838 TC PPD (25 pxg/ml) 
(50 ~g/ml) (1 vg/ml) 
Total With BCG a No BCG 
therapy therapy 
Group A 
Number of patients reactive/total tested (%) 
Number of (+) tests/total tests (%) 
Group B 
Number of patients reactive/total tested (%) 
Number of (+) tests/total tests (%) 
9/10 5/7 4/7 2/2 2/5 
(90) (71) (57) (100) (40) 
31/44 5/9 5/9 2/3 3/6 
(70) (56) (56) (67) (50) 
1/1 - 1/1 1/1 
(100) - (100) (100) 
2/2 0/0 1/1 1/1 
(100) (0) (100) (100) 
a Patients who had received BCG as part of either their primary therapy or anti-tuberculosis immunization programs 
Table 5. Lymphocyte subpopulations during therapy of patients with localized disease 
Absolute number of Number of 29 ° C RFC Number of 4 ° C RFC 
lymphocytes per mm 3 tests in % tests in % 
range/total tests (%) range/total tests (%) 
Number of 
tests in 
range/total tests ~)  
Group A 
< 500 6/11 (55) < 25 3/16 (19) < 25 
500--1000 2/11 (18) 25--47 8/16 (50) 25--67 
> 1000 3/11 (27) > 47 5/16 (31) > 67 
Group B 
< 500 3/7 (43) < 25 2/9 (22) < 25 
500-1000 4/7 (57) 25-47 6/9 (67) 25-67 







in LMI ,  and this sensitivity could be attr ibuted to B C G  
immunotherapy  or to known prior sensitization. 
The results of  rosette assays during therapy of  pa- 
tients with localized disease are summarized in Table 5. 
Of the assays in group A patients, nearly one third of  
the measurements  of  the 29 ° C R F C  and all of  the mea- 
surements of  4 ° C R F C  and all of  the measurements  of  
4 ° C R F C  subpopulat ions were in the normal  range, in 
contras t  to the lower percentage of  normal  values in the 
group B patients. 
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Table 6. Immunologic reactivity and subsequent clinical course after initial therapy of patients with localized disease 
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Delayed cutaneous hypersensitivity 
KLH SKSD Mumps PPD 5838 KC1 5838 TC KC1 5838 HMP 
Group A 
Number of patients reactive/total tested (%) 
Number of (+) tests/total tests (%) 
Group B 
Number of patients reactive/total tested (%) 
Number of (+) tests/total tests (%) 
, 4/5 12/12 3/3 3/9 5/5 2/3 2/6 
(80) (100) (100) (33) (100) (67) (33) 
4/5 15/15 3/3 3/18 8/8 2/3 2/6 
(80) (100) (100) (17) (100) (67) (33) 
5/9 12/14 6/7 6/14 4/4 6/6 5/5 
(56) (86) (86) (43) (100) (100) (100) 
9/14 18/23 7/10 7/25 4/4 6/8 4/15 
(64) (78) (70) (28) (100) (75) (27) 
Leukocyte migration inhibition 
5838 TC 5838 TC PPD (25 ~g/ml) 
(50 ~g/ml) (1 ~g/ml) 
Total With BCG" No BCG 
therapy therapy 
Group A 
Number of patients reactive/total tested (%) 
Number of (+) tests/total tests (%) 
Group B 
Number of patients reactive/total tested (%) 
Number of (+) tests/total tests (%) 
17/23 8/14 4/8 1/1 3/7 
(74) (56) (50) (100) (43) 
25/51 10/18 5/12 2/3 3/9 
(49) (56) (42) (67) (33) 
14/14 7/11 6/9 4/4 2/5 
(100) (64) (67) (100) (40) 
38/53 8/16 8/13 5/6 3/7 
(72) (50) (62) (83) (43) 
a Patients who had received BCG as part of either their primary therapy or anti-tuberculosis immunization programs outside the United 
States 
Differences between groups are not statistically significant by chi-square analysis 
Responses after Initial Therapy 
D C H  and LMI  responses after completion of  initial 
therapy of  patients with localized disease are shown in 
Table 6. Patients who remained free of  disease (group 
A) retained D C H  to recall antigens, with the exception 
of  a single patient who was unreactive to K L H  but re- 
mains disease-free after more than 2 years. However, 
patients who relapsed (group B) were frequently unreac- 
tive to the standard recall antigens, probably a result of  
immunosuppressive effects of  recurrent disease or cyto- 
toxic chemotherapy or both. In contrast, the responses 
to the TAAs  appeared to be roughly equal for each an- 
tigen in both groups of  patients. In direct LMI,  all group 
B patients were reactive to the higher concentration of  
tumor extract in comparison to the approximately one 
fourth of  group A patients who remained persistently 
negative to this concentration of  TAA. Among the pa- 
tients in group B who were reactive to PPD in LMI, 
three patients were not on immunotherapy and were not 
known to have received BCG elsewhere. 
Table 7 summarizes the results of  rosette assays fol- 
lowing completion of  therapy in group A patients. There 
was a general trend for counts to return toward normal. 
However, the percentage of  29 ° C RFC remained low in 
71% of the tests. Similar data were not available for the 
interval between completion of  therapy and relapse for 
group B patients. 
Effects of Therapy on DCH 
We were interested in the longitudinal changes in the 
magnitudes of  D C H  responses and the effects of  immu- 
notherapy and cytotoxic radio- and chemotherapy on 
these responses. Sequential data from 29 group A pa- 
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Table 7. Lymphocyte subpopulations after therapy of patients with localized disease in remission 
Absolute number of Number of 29 ° C RFC Number of 4 ° C RFC Number of 
lymphocytes per mm 3 tests in % tests in % tests in 
range/total tests (%) range/total tests (%) range/total tests (%) 
< 500 1/15 (7) < 25 1/14 (7) < 25 0 (0) 
500-1000 2/15 (13) 25-47 9/14 (64) 25-67 1 (33) 
> 1000 12/15 (80) > 47 4/14 (29) > 67 2 (67) 
tients, including five patients who received BCG immu- 
notherapy, and 17 group B patients showed that radio- 
therapy and chemotherapy given intermittently for 6 
months had no apparent suppressive effect on DCH and 
cessation of treatment did not appear to be associated 
with increased magnitude of response. Although the 
number of group A patients who received BCG is small 
and does not permit firm conclusions, no pattern of 
reactivity to the antigens (aside from PPD) individually 
or in toto clearly separated patients on immunotherapy 
from those receiving standard therapy alone. 
Discussion 
Because Ewing's sarcoma is a rare tumor, most reports 
concerning this neoplasm have dealt with treatment 
methods and results involving relatively small numbers 
of patients or with histopathologic descriptions of the 
tumor. Earlier we reported the results of LMI studies in 
29 patients with Ewing's sarcoma (McCoy et al., 1977). 
This paper expands the previous report and includes 
data on the immunologic responses of Ewing's sarcoma 
patients and the relationship of these responses to clinical 
status. We also report the results of BCG immunother- 
apy on immunologic responses, both in patients with 
clinically localized disease and in those with widely dis- 
seminated disease. 
Skin testing for DCH has been used extensively to 
assess the immune competence of cancer patients. Many 
studies have employed standard recall antigens, but in 
most studies the results of testing with these antigens 
have not been very useful for diagnosis or prognosis. 
Our results with the recall antigens SKSD, mumps, and 
PPD reaffirm the experiences of others: nearly all pa- 
tients tested at the time of diagnosis with these sub- 
stances responded alike, regardless of the extent of dis- 
ease or subsequent clinical course. Lack of reactivity 
was associated with poor prognosis but, with few excep- 
tions, patients with negative SKSD or mumps skin tests 
had readily apparent, often progressive disease and a 
short survival after manifestation of nonreactivity to 
these antigens. 
Tests for DCH involving sensitization and subse- 
quent rechallenge with an antigen to which the patient 
had not been previously exposed, such as DNCB, have 
been reported to be more sensitive prognostic indicators 
(Eilber and Morton, 1970; Pinsky et al., 1971; Wells et 
al., 1973), and our experience with KLH testing in 
Ewing's sarcoma is consistent with this. Employing a 
sensitizing dose of 2.5 mg [25 times the dose needed to 
sensitize normals (Paul et al., 1974)] and a test dose of 
0.1 mg, we found that group A patients had a much 
higher frequency of responses 15 mm or greater in di- 
ameter than did either group B or group C patients. 
Whether smaller sensitizing or test doses would elicit 
more distinct differences, as was reported with lower 
sensitizing doses in patients with Hodgkin's disease (E1- 
tringham and Kaplan, 1973), is speculative. 
Skin test reactivity to the Ewing's tumor extracts did 
not correlate with the clinical course of patients. In fact, 
a high proportion of patients reacted to these prepara- 
tions during all phases of testing and regardless of the 
extent of disease. In contrast, in a study of a large group 
of patients with acute leukemia, Char et al. (1973) found 
a significantly higher percentage of positive responses to 
extracts of leukemic blast cells when the patients were in 
remission; serial tests with autologous blast extracts 
seemed to correlate with clinical status, with positive 
responses during remission becoming negative at re- 
lapse, and patients who had positive responses had a 
slight increase in remission duration. One possible expla- 
nation for the difference between these two studies may 
relate to the specificities of the tumor extracts used in 
DCH testing. The extracts of leukemic blast cells ap- 
peared to give disease-specific DCH reactions (Char et 
al., 1973). Although a high proportion of Ewing's sarco- 
ma patients had positive skin test responses to the ex- 
tracts of the 5838 tumor, these extracts were selected for 
intracutaneous testing because of specificity in LMI 
tests (McCoy et al., 1977), and the specificity of these 
preparations in skin testing has not been determined. In 
fact, two patients referred to the National Cancer Insti- 
tute with Ewing's sarcoma, but subsequently found to 
have malignant lymphoma of bone, had positive DCH 
responses to the extracts prior to therapy. 
In contrast to the experience of others (Papatestas et 
al., 1976; Riesco, 1970), we found no significant corre- 
lation between absolute lymphocyte counts at diagnosis 
and subsequent clinical course. Many of the patients in 
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each group had low levels of  29 ° C R F C ,  as we reported 
earlier for lung and breast  cancer  patients (Oldham et 
al., 1976; Weese et al., 1977), and a lower propor t ion of  
patients with advanced disease had 29 ° C R F C  percent- 
ages in the normal  range. Absolute  lymphocyte  counts 
decreased during therapy but  returned toward  normal  
levels in patients who remained clinically free of  disease; 
however,  29 ° C R F C s  remained at low levels in nearly 
two-thirds of  these patients. 
As  shown in Table 6, there was a tendency for more 
frequent reactivi ty in direct LMI  testing in patients who 
relapsed or had  tumor  present. The only patients persis- 
tently unreactive in LMI  were those who remained dis- 
ease-free. We have noted similar trends in patients with 
lung and breas t  cancer  and will repor t  these findings in 
detail elsewhere. It may  be that  continued stimulation by  
residual tumor  antigens is required for persistence of  
LMI  reactivity. 
We  saw no noticeable effect of  B C G  immunother-  
apy  on reactivi ty except for conversion of  the PPD skin 
test and a higher incidence of  reactivi ty to P P D  in LMI.  
However ,  neither of  these was of  prognost ic  signifi- 
cance. This lack of  detectable effect of  immunotherapy  
on measurable  immunologic  functions is similar to that  
reported in acute leukemia (Leventhal et al., 1973) and 
in lung cancer  (Oldham et al., 1976). B C G  immunother-  
apy  was well tolerated, with the only complicat ion being 
a mild secondary  infection of  a scarification site in a 7- 
year-old girl. Neither B C G  nor B C G  plus allogeneic 
cells appeared  to alter what  was usually a relentless pro- 
gression toward  death in patients who had metastases at 
t ime of  diagnosis,  nor did B C G  appear  to have any ef- 
fect on the course of  the disease in patients who re- 
lapsed. Of  nine patients with localized disease, who were 
at high risk for relapse, four were randomized to stan- 
dard  t reatment  plus no further therapy;  three have died 
of  recurrent  tumor  or complicat ions related to t reatment  
after relapse; only one remains in remission. Of  the five 
patients who received s tandard t reatment  plus B C G  im- 
munotherapy,  only one has relapsed, a 25-year-old male 
who developed multiple pu lmonary  metastases 18 
months after the initial diagnosis. Addi t ional  patients 
are being accumulated to determine whether B C G  im- 
munotherapy  m a y  be of  significant value in such pa- 
tients at high risk for recurrence. 
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